FBR & Co restated their outperform rating on shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in a research note released on Wednesday. They currently have a $11.00 price target on the stock, up from their previous price target of $9.00.
Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity set a $10.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock a buy rating in a research report on Saturday, March 11th. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, March 20th. HC Wainwright upped their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $12.00 and gave the stock a positive rating in a research report on Friday, March 3rd. Finally, Leerink Swann reissued an outperform rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a report on Sunday, December 4th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Aurinia Pharmaceuticals presently has a consensus rating of Buy and an average price target of $9.25.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 8.02 on Wednesday. The stock’s 50 day moving average is $5.48 and its 200 day moving average is $3.56. The firm’s market cap is $428.49 million. Aurinia Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $10.54.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Mideast Time and is the sole property of of Mideast Time. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.mideasttime.com/aurinia-pharmaceuticals-auph-outperform-rating-reiterated-at-fbr-co/1589250.html.
Several hedge funds and other institutional investors have recently bought and sold shares of AUPH. Creative Planning bought a new position in Aurinia Pharmaceuticals during the third quarter worth approximately $181,000. Oxford Asset Management purchased a new position in Aurinia Pharmaceuticals during the fourth quarter valued at about $211,000. Redmile Group LLC increased its position in Aurinia Pharmaceuticals by 560.4% in the third quarter. Redmile Group LLC now owns 187,610 shares of the company’s stock valued at $565,000 after buying an additional 159,200 shares in the last quarter. SG Americas Securities LLC purchased a new position in Aurinia Pharmaceuticals during the third quarter valued at about $1,123,000. Finally, Acuta Capital Partners LLC purchased a new position in Aurinia Pharmaceuticals during the fourth quarter valued at about $2,100,000. 7.96% of the stock is owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.